Literature DB >> 21723415

FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles.

David E Godler1, Howard R Slater, Quang M Bui, Michele Ono, Freya Gehling, David Francis, David J Amor, John L Hopper, Randi Hagerman, Danuta Z Loesch.   

Abstract

Fragile X syndrome (FXS) is caused by loss of the fragile X mental retardation gene protein product (FMRP) through promoter hypermethylation, which is usually associated with CGG expansion to full mutation size (>200 CGG repeats). Methylation-sensitive Southern blotting is the current gold standard for the molecular diagnosis of FXS. For females, Southern blotting provides the activation ratio (AR), which is the proportion of unmethylated alleles on the active X chromosome. Herein, we examine the relationship of FMRP expression with methylation patterns of two fragile X-related epigenetic elements (FREE) analyzed using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry and the AR. We showed that the differential methylation of the FREE2 sequence within fragile X mental retardation gene intron 1 was related to depletion of FMRP expression. We also show that, using the combined cohort of 12 females with premutation (55 to 200 CGG repeats) and 22 females with full mutation alleles, FREE2 methylation analysis was superior to the AR as a predictor of the proportion of FMRP-positive cells in blood. Because matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry is amenable to high-throughput processing and requires minimal DNA, these findings have implications for routine FXS testing and population screening.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723415      PMCID: PMC3157613          DOI: 10.1016/j.jmoldx.2011.05.006

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  47 in total

1.  Application of robust pedigree analysis in studies of complex genotype-phenotype relationships in fragile X syndrome.

Authors:  D Z Loesch; R M Huggins; A K Taylor
Journal:  Am J Med Genet       Date:  2002-01-15

2.  Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome.

Authors:  W E Kaufmann; M T Abrams; W Chen; A L Reiss
Journal:  Am J Med Genet       Date:  1999-04-02

3.  FMRP expression as a potential prognostic indicator in fragile X syndrome.

Authors:  F Tassone; R J Hagerman; D N Iklé; P N Dyer; M Lampe; R Willemsen; B A Oostra; A K Taylor
Journal:  Am J Med Genet       Date:  1999-05-28

4.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

5.  A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome.

Authors:  Stela Filipovic-Sadic; Sachin Sah; Liangjing Chen; Julie Krosting; Edward Sekinger; Wenting Zhang; Paul J Hagerman; Timothy T Stenzel; Andrew G Hadd; Gary J Latham; Flora Tassone
Journal:  Clin Chem       Date:  2010-01-07       Impact factor: 8.327

6.  Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.

Authors:  Roberta Pietrobono; Maria Grazia Pomponi; Elisabetta Tabolacci; Ben Oostra; Pietro Chiurazzi; Giovanni Neri
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

7.  Rapid antibody test for fragile X syndrome.

Authors:  R Willemsen; S Mohkamsing; B de Vries; D Devys; A van den Ouweland; J L Mandel; H Galjaard; B Oostra
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

Review 8.  Phenotypic variation and FMRP levels in fragile X.

Authors:  Danuta Z Loesch; Richard M Huggins; Randi J Hagerman
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004

9.  A ligation assay for multiplex analysis of CpG methylation using bisulfite-treated DNA.

Authors:  Christina Dahl; Per Guldberg
Journal:  Nucleic Acids Res       Date:  2007-11-12       Impact factor: 16.971

10.  Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements.

Authors:  Marcel W Coolen; Aaron L Statham; Margaret Gardiner-Garden; Susan J Clark
Journal:  Nucleic Acids Res       Date:  2007-09-13       Impact factor: 16.971

View more
  16 in total

1.  A Set of Assays for the Comprehensive Analysis of FMR1 Alleles in the Fragile X-Related Disorders.

Authors:  Bruce E Hayward; Yifan Zhou; Daman Kumari; Karen Usdin
Journal:  J Mol Diagn       Date:  2016-08-12       Impact factor: 5.568

2.  Abnormal methylation status of FBXW10 and SMPD3, and associations with clinical characteristics in clear cell renal cell carcinoma.

Authors:  Jinyou Wang; Jian Li; Jun Gu; Jian Yu; Shicheng Guo; Yao Zhu; Dingwei Ye
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

Review 3.  Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells.

Authors:  Shira Yanovsky-Dagan; Hagar Mor-Shaked; Rachel Eiges
Journal:  World J Stem Cells       Date:  2015-06-26       Impact factor: 5.326

4.  Novel methylation markers of the dysexecutive-psychiatric phenotype in FMR1 premutation women.

Authors:  Kim M Cornish; Claudine M Kraan; Quang Minh Bui; Mark A Bellgrove; Sylvia A Metcalfe; Julian N Trollor; Darren R Hocking; Howard R Slater; Yoshimi Inaba; Xin Li; Alison D Archibald; Erin Turbitt; Jonathan Cohen; David E Godler
Journal:  Neurology       Date:  2015-03-25       Impact factor: 9.910

5.  Relationships between age and epi-genotype of the FMR1 exon 1/intron 1 boundary are consistent with non-random X-chromosome inactivation in FM individuals, with the selection for the unmethylated state being most significant between birth and puberty.

Authors:  David E Godler; Yoshimi Inaba; Elva Z Shi; Cindy Skinner; Quang M Bui; David Francis; David J Amor; John L Hopper; Danuta Z Loesch; Randi J Hagerman; Charles E Schwartz; Howard R Slater
Journal:  Hum Mol Genet       Date:  2013-01-10       Impact factor: 6.150

6.  A novel methylation PCR that offers standardized determination of FMR1 methylation and CGG repeat length without southern blot analysis.

Authors:  Marina Grasso; Elles M J Boon; Stela Filipovic-Sadic; Patrick A van Bunderen; Elena Gennaro; Ru Cao; Gary J Latham; Andrew G Hadd; Domenico A Coviello
Journal:  J Mol Diagn       Date:  2013-10-29       Impact factor: 5.568

7.  Fragile X syndrome in a male with methylated premutation alleles and no detectable methylated full mutation alleles.

Authors:  Bruce Hayward; Inna Loutaev; Xiaohua Ding; Sarah L Nolin; Audrey Thurm; Karen Usdin; Carolyn B Smith
Journal:  Am J Med Genet A       Date:  2019-07-29       Impact factor: 2.578

Review 8.  Mass spectrometry as a tool for studying autism spectrum disorder.

Authors:  Alisa G Woods; Armand G Ngounou Wetie; Izabela Sokolowska; Stefanie Russell; Jeanne P Ryan; Tanja Maria Michel; Johannes Thome; Costel C Darie
Journal:  J Mol Psychiatry       Date:  2013-05-21

Review 9.  Detection of skewed X-chromosome inactivation in Fragile X syndrome and X chromosome aneuploidy using quantitative melt analysis.

Authors:  David E Godler; Yoshimi Inaba; Charles E Schwartz; Quang M Bui; Elva Z Shi; Xin Li; Amy S Herlihy; Cindy Skinner; Randi J Hagerman; David Francis; David J Amor; Sylvia A Metcalfe; John L Hopper; Howard R Slater
Journal:  Expert Rev Mol Med       Date:  2015-07-01       Impact factor: 5.600

10.  Post-weaning selenium and folate supplementation affects gene and protein expression and global DNA methylation in mice fed high-fat diets.

Authors:  Emma N Bermingham; Shalome A Bassett; Wayne Young; Nicole C Roy; Warren C McNabb; Janine M Cooney; Di T Brewster; William A Laing; Matthew P G Barnett
Journal:  BMC Med Genomics       Date:  2013-03-05       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.